Drug Enforcement Administration, Department of Justice.
With the issuance of this final rule, the Drug Enforcement Administration places beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide), also known as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-propanamide, including its isomers, esters, ethers, Start Printed Page 20024salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. This rule continues the imposition of the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle beta-hydroxythiofentanyl.
This final rule is effective May 8, 2019.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Lynnette M. Wingert, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812.
End Further Info
Start Supplemental Information
The Controlled Substances Act (CSA) provides that proceedings for the issuance, amendment, or repeal of the scheduling of any drug or other substance may be initiated by the Attorney General (1) on his own motion; (2) at the request of the Secretary of the Department of Health and Human Services (HHS),
or (3) on the petition of any interested party. 21 U.S.C. 811(a). This action was initiated by the former Acting Administrator of the Drug Enforcement Administration (DEA) on his own motion and an evaluation of all other relevant data by the DEA, and is supported by a recommendation from the Assistant Secretary for Health of the HHS (Assistant Secretary). This action continues the imposition of the regulatory controls and administrative, civil, and criminal sanctions of schedule I controlled substances on any person who handles or proposes to handle beta-hydroxythiofentanyl.
On May 12, 2016, the DEA published a final order in the Federal Register amending 21 CFR 1308.11(h) to temporarily place beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N- phenylpropionamide) in schedule I of the CSA pursuant to the temporary scheduling provisions of 21 U.S.C. 811(h). 81 FR 29492. That temporary order was effective on the date of publication, and was based on findings by the Acting Administrator of the DEA that the temporary scheduling of beta-hydroxythiofentanyl was necessary to avoid an imminent hazard to public safety pursuant to 21 U.S.C. 811(h)(1). Section 201(h)(2) of the CSA 
requires that the temporary control of this substance expire two years from the effective date of the scheduling order, which was May 12, 2018. However, the CSA also provides that during the pendency of proceedings under 21 U.S.C. 811(a)(1) with respect to the substance, the temporary scheduling of that substance may be extended for up to one year. Id. Accordingly, on May 10, 2018, the DEA extended the temporary scheduling of beta-hydroxythiofentanyl by one year, until May 12, 2019. 83 FR 21834. On May 10, 2018, the DEA published a notice of proposed rulemaking (NPRM) to permanently control beta-hydroxythiofentanyl in schedule I of the CSA. 83 FR 21826.
DEA and HHS Eight Factor Analyses
On April 27, 2018, the HHS provided the DEA with a scientific and medical evaluation and scheduling recommendation for beta-hydroxythiofentanyl entitled “Basis for the recommendation to place β-hydroxythiofentanyl and its isomers, esters, ethers, salts and salts of isomers, esters and ethers into Schedule I of the Controlled Substances Act (CSA).” After considering the eight factors in 21 U.S.C. 81l(c), including consideration of the substance's abuse potential, lack of legitimate medical use in the United States, and lack of accepted safety for use under medical supervision, the Assistant Secretary of the HHS recommended that beta-hydroxythiofentanyl be controlled in schedule I of the CSA. In response, the DEA conducted its own eight-factor analysis of beta-hydroxythiofentanyl and concluded that this substance warrants control in schedule I of the CSA. Both the DEA and HHS 8-Factor analyses are available in their entirety under the tab “Supporting Documents” of the public docket for this action at http://www.regulations.gov under Docket Number “DEA-484.”
Determination to Schedule beta-Hydroxythiofentanyl
After a review of the available data, including the scientific and medical evaluation and the scheduling recommendation from the HHS, the former Acting Administrator of the DEA published a NPRM entitled “Schedules of Controlled Substances: Placement of beta-Hydroxythiofentanyl into Schedule I,” proposing to control beta-hydroxythiofentanyl. 83 FR 21826, May 10, 2018. The NPRM provided an opportunity for interested persons to file a request for hearing in accordance with the DEA regulations on or before June 11, 2018. No requests for such a hearing were received by the DEA. The NPRM also provided an opportunity for interested persons to submit written comments on the proposal up to June 11, 2018. All of the comments received are summarized below, along with the DEA's response.
The DEA received 25 comments on the proposed rule to control beta-hydroxythiofentanyl in schedule I of the CSA. Ten commenters were in favor of controlling beta-hydroxythiofentanyl as a schedule I controlled substance, and one commenter was in favor of controlling beta-hydroxythiofentanyl as a schedule II controlled substance. One commenter supporting the rule submitted responses nine times (generating eight duplicative responses). Six commenters submitted responses that were outside the scope of the action.
Support of the Proposed Rule
Ten commenters supported controlling beta-hydroxythiofentanyl as a schedule I controlled substance. One commenter urged the DEA to maintain the status of beta-hydroxythiofentanyl as a schedule I controlled substance. Another commenter stated it is concerning that the DEA was unable to permanently control beta-hydroxythiofentanyl as a schedule I substance within the two year time frame. Three commenters stated that because beta-hydroxythiofentanyl has no approved medical use, it should be controlled as a schedule I substance. Specifically, one commenter stated that placing beta-hydroxythiofentanyl in a different schedule within the CSA would foster recreational use of this substance. Further, four commenters noted that beta-hydroxythiofentanyl and other fentanyl derivatives pose significant health risk to the public. Specifically, one commenter stated that fentanyl and its derivatives have been found in numerous samples of other street drugs such as heroin and cocaine and classifying beta-hydroxythiofentanyl as a schedule I controlled substance illustrates the true Start Printed Page 20025stance of the government in protecting the public.
DEA Response: The DEA agrees with the comments in support for this rulemaking. With regard to the comment related to the timeliness of permanent control of beta-hydroxythiofentanyl by the DEA, the DEA is in compliance with the provisions of a temporary scheduling action. Section 201(h)(2) of the CSA 
requires that the temporary control of a substance expires two years from the effective date of the scheduling order. The Administrator may, during the pendency of proceedings under subsection 21 U.S.C. 811(a)(1), extend the temporary scheduling for up to one year.
Comments Suggesting Placement in Schedule II
One commenter stated that beta-hydroxythiofentanyl similar to fentanyl should be placed in schedule II of the CSA because it is an analog of fentanyl and has some medical use in the United States.
DEA Response: The Assistant Secretary, through a letter dated January 13, 2016, notified the former Acting Administrator of the DEA that beta-hydroxythiofentanyl is not the subject of any approved new drug application (NDA) or investigational new drug application (IND). According to HHS, there is no approved drug product containing beta-hydroxythiofentanyl. HHS concluded that beta-hydroxythiofentanyl lacks accepted medical use in the United States. If a controlled substance has no such currently accepted medical use, it must be placed in schedule I.
One commenter expressed concerns about the roles of phones in classroom and wants smart phones out of public schools. Another commenter highlighted the gap in medical education system and emphasized the need for physicians to handle difficulties associated with prescription drug abuse. Another commenter stated that words matter when handling complex issues like powerful prescription drugs. Three commenters misinterpreted beta-hydroxythiofentanyl as fentanyl and expressed that access to their fentanyl medications, especially the fentanyl transdermal patch, should not be denied.
DEA Response: The comment about phones in classrooms and the comment that words matter when handling powerful prescription drugs are unrelated to this scheduling action.
With regard to the gap in medical education system and the need to educate physicians to tackle prescription drug abuse, the DEA has worked aggressively to improve its communication and cooperation with registrant medical professionals by maintaining an open dialogue with national associations such as the American Medical Association, Federation of State Medical Boards, and other groups to address diversion problems and educate the medical community on improving prescribing practices. In May 2018, the DEA initiated a nationwide program to train individual practitioners through Practitioner Diversion Awareness Conferences (PDACs) throughout the country. In addition to the PDAC training, the DEA has also sent correspondence to 1.3 million prescribers nationwide, alerting them of the Centers for Disease Control and Prevention (CDC) recommendation (part of CDC's Prescribing Guideline for Chronic Pain) for opioid prescribing for acute pain and alerted practitioners to a free training webinar available from CDC. The DEA is also working on similar correspondence to alert these same practitioners about resources available from the Substance Abuse and Mental Health Services Administration (SAMHSA) to locate substance abuse treatment providers in their state.
This rule will not affect patient access to FDA-approved fentanyl medications (such as the fentanyl transdermal patch) because the rule is limited to beta-hydroxythiofentanyl, a synthetic opioid with no currently accepted medical use in treatment in the United States.
Based on consideration of all comments, the scientific and medical evaluation and accompanying recommendation of the HHS, and the DEA's consideration of its own eight-factor analysis, the DEA finds that these facts and all other relevant data constitute substantial evidence of potential for abuse of beta-hydroxythiofentanyl. As such, the DEA is scheduling beta-hydroxythiofentanyl as a controlled substance under the CSA.
Determination of Appropriate Schedule
The CSA establishes five schedules of controlled substances known as schedules I, II, III, IV, and V. The CSA also outlines the findings required to place a drug or other substance in any particular schedule. 21 U.S.C. 812(b). After consideration of the analysis, recommendation of the Assistant Secretary for HHS, and review of all other available data, the Acting Administrator of the DEA, pursuant to 21 U.S.C. 811(a) and 21 U.S.C. 812(b)(1), finds that:
1. beta-Hydroxythiofentanyl has a high potential for abuse;
2. beta-Hydroxythiofentanyl has no currently accepted medical use in treatment in the United States; and
3. There is a lack of accepted safety for use of beta-hydroxythiofentanyl under medical supervision.
Based on these findings, the Acting Administrator of the DEA concludes that beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, warrants control in schedule I of the CSA. 21 U.S.C. 812(b)(1).
Requirements for Handling beta-Hydroxythiofentanyl
Upon the effective date of this final rule, beta-hydroxythiofentanyl will continue 
to be subject to the CSA's schedule I regulatory controls and administrative, civil, and criminal sanctions applicable to the manufacture, distribution, dispensing, importing, exporting, research, and conduct of instructional activities, including the following:
1. Registration. Any person who handles (manufactures, distributes, dispenses, imports, exports, engages in research, or conducts instructional activities or chemical analysis with, or possesses) beta-hydroxythiofentanyl, or who desires to handle beta-hydroxythiofentanyl, must be registered with the DEA to conduct such activities pursuant to 21 U.S.C. 822, 823, 957, and 958, and in accordance with 21 CFR parts 1301 and 1312.
2. Disposal of stocks. beta-Hydroxythiofentanyl must be disposed of in accordance with 21 CFR part 1317, in addition to all other applicable federal, state, local, and tribal laws.
3. Security. beta-Hydroxythiofentanyl is subject to schedule I security requirements and must be handled and stored pursuant to 21 U.S.C. 821, 823, and in accordance with 21 CFR 1301.71-1301.93.Start Printed Page 20026
4. Labeling and Packaging. All labels and labeling for commercial containers of beta-hydroxythiofentanyl must comply with 21 U.S.C. 825 and 958(e) and must conform with 21 CFR part 1302.
5. Quota. Only registered manufacturers are permitted to manufacture beta-hydroxythiofentanyl in accordance with a quota assigned pursuant to 21 U.S.C. 826 and in accordance with 21 CFR part 1303.
6. Inventory. Every DEA registrant whose registration currently authorizes handling beta-hydroxythiofentanyl and who possesses any quantity of beta-hydroxythiofentanyl on the effective date of this final rule must maintain an inventory of all stocks of beta-hydroxythiofentanyl on hand, pursuant to 21 U.S.C. 827 and 958, and in accordance with 21 CFR 1304.03, 1304.04, and 1304.11. Any person who becomes registered with the DEA on or after the effective date of this final rule must take an initial inventory of all stocks of beta-hydroxythiofentanyl on hand pursuant to 21 U.S.C. 827 and 958, and in accordance with 21 CFR 1304.03, 1304.04, and 1304.11.
After the initial inventory, every DEA registrant must take a new inventory of all stocks of controlled substances (including beta-hydroxythiofentanyl) on hand every two years pursuant to 21 U.S.C. 827 and 958, and in accordance with 21 CFR 1304.03, 1304.04, and 1304.11.
7. Records and Reports. Every DEA registrant must maintain records and submit reports with respect to beta-hydroxythiofentanyl, pursuant to 21 U.S.C. 827 and 958(e), and in accordance with 21 CFR parts 1304 and 1312.
8. Order Forms. Every DEA registrant who distributes beta-hydroxythiofentanyl must comply with the order form requirements, pursuant to 21 U.S.C. 828, and 21 CFR part 1305.
9. Importation and Exportation. All importation and exportation of beta-hydroxythiofentanyl must be in compliance with 21 U.S.C. 952, 953, 957, and 958, and in accordance with 21 CFR part 1312.
10. Liability. Any activity involving beta-hydroxythiofentanyl not authorized by, or in violation of, the CSA or its implementing regulations is unlawful, and may subject the person to administrative, civil, and/or criminal sanctions.
Executive Orders 12866, 13563, and 13771, Regulatory Planning and Review, Improving Regulation and Regulatory Review, and Reducing Regulation and Controlling Regulatory Costs
In accordance with 21 U.S.C. 811(a), this scheduling action is subject to formal rulemaking procedures done “on the record after opportunity for a hearing,” which are conducted pursuant to the provisions of 5 U.S.C. 556 and 557. The CSA sets forth the criteria for scheduling a drug or other substance. Such actions are exempt from review by the Office of Management and Budget (OMB) pursuant to section 3(d)(1) of Executive Order 12866 and the principles reaffirmed in Executive Order 13563.
This final rule does not meet the definition of an Executive Order 13771 regulatory action. OMB has previously determined that formal rulemaking actions concerning the scheduling of controlled substances, such as this rule, are not significant regulatory actions under Section 3(f) of Executive Order 12866.
This regulation meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 to eliminate drafting errors and ambiguity, minimize litigation, provide a clear legal standard for affected conduct, and promote simplification and burden reduction.
This rulemaking does not have federalism implications warranting the application of Executive Order 13132. The rule does not have substantial direct effects on the States, on the relationship between the national government and the States, or the distribution of power and responsibilities among the various levels of government.
Executive Order 13175, Consultation and Coordination With Indian Tribal Governments
This rule does not have tribal implications warranting the application of Executive Order 13175. It does not have substantial direct effects on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes.
Regulatory Flexibility Act
The Acting Administrator, in accordance with the Regulatory Flexibility Act, 5 U.S.C. 601-602, has reviewed this final rule and by approving it, certifies that it will not have a significant economic impact on a substantial number of small entities. On May 12, 2016, the DEA published a final order to temporarily place beta-hydroxythiofentanyl in schedule I of the CSA pursuant to the temporary scheduling provisions of 21 U.S.C. 811(h). On May 10, 2018, the DEA published a temporary scheduling order extending the temporary placement of beta-hydroxythiofentanyl in schedule I of the CSA for up to one year pursuant to 21 U.S.C. 811(h)(2). Accordingly, all entities that currently handle or plan to handle beta-hydroxythiofentanyl have already established and implemented the systems and processes required to handle this substance. There are currently 20 registrations authorized to handle beta-hydroxythiofentanyl, as well as a number of registered analytical labs that are authorized to handle schedule I controlled substances generally. These 20 registrations represent 18 entities, of which 14 are small entities. Therefore, the DEA estimates 14 small entities are affected by this rule.
A review of the 20 registrations indicates that all entities that currently handle beta-hydroxythiofentanyl also handle other schedule I controlled substances, and have established and implemented (or maintain) the systems and processes required to handle beta-hydroxythiofentanyl. Therefore, the DEA anticipates that this rule will impose minimal or no economic impact on any affected entities; and thus, will not have a significant economic impact on any of the 14 affected small entities. Therefore, the DEA has concluded that this rule will not have a significant effect on a substantial number of small entities.
Unfunded Mandates Reform Act of 1995
In accordance with the Unfunded Mandates Reform Act (UMRA) of 1995, 2 U.S.C. 1501 et seq., the DEA has determined and certifies that this action will not result in any Federal mandate that may result “in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted for inflation) in any one year . . .” Therefore, neither a Small Government Agency Plan nor any other action is required under UMRA of 1995.Start Printed Page 20027
Paperwork Reduction Act of 1995
This action does not impose a new collection of information under the Paperwork Reduction Act of 1995. 44 U.S.C. 3501-3521. This action will not impose recordkeeping or reporting requirements on State or local governments, individuals, businesses, or organizations. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
Congressional Review Act
This final rule is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act (CRA)). This rule will not result in: An annual effect on the economy of $100,000,000 or more; a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based enterprises to compete with foreign-based enterprises in domestic and export markets. However, pursuant to the CRA, the DEA has submitted a copy of this final rule to both Houses of Congress and to the Comptroller General.
Determination To Make Rule Effective Immediately
The DEA is making the rule effective on the date of publication in the Federal Register as allowed under the good cause exception in 5 U.S.C. 553(d)(3). This final rule amends the regulations to permanently control beta-hydroxythiofentanyl in schedule I of the CSA. This action continues control of the substance as it is currently controlled until May 12, 2019 by virtue of the temporary scheduling order (83 FR 21834, May 10, 2018). The May 2018 temporary scheduling order extended temporary control of the substance, which was first established in the May 10, 2016, final order. 81 FR 29492. That May 2016 final order was effective on the date of publication, and was based on findings by the Acting Administrator of the DEA that the temporary scheduling of beta-hydroxythiofentanyl was necessary to avoid an imminent hazard to the public safety pursuant to 21 U.S.C. 811(h)(1). Therefore, the DEA believes it is unnecessary and contrary to the public interest to delay the effectiveness of this final rule by 30 days.
Start List of Subjects
End List of Subjects
- Administrative practice and procedure
- Drug traffic control
- Reporting and recordkeeping requirements
For the reasons set out above, the DEA amends 21 CFR part 1308 as follows:
PART 1308—SCHEDULES OF CONTROLLED SUBSTANCES
Start Amendment Part
1. The authority citation for 21 CFR part 1308 continues to read as follows:End Amendment Part
Start Amendment Part
2. In § 1308.11: End Amendment Part
Start Amendment Part
a. Redesignate paragraphs (b)(16) through (65) as (b)(17) through (66); End Amendment Part
Start Amendment Part
b. Add new paragraph (b)(16); and End Amendment Part
Start Amendment Part
c. Remove and reserve paragraph (h)(3). End Amendment Part
The addition reads as follows:
* * * * *
(b) * * *
|(16) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide (Other name: beta-Hydroxythiofentanyl)||9836|
* * * * *
End Supplemental Information
Dated: May 2, 2019.
[FR Doc. 2019-09479 Filed 5-7-19; 8:45 am]
BILLING CODE 4410-09-P